Skip to content

Author

K. Chlichlia

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Immune Evasion by Neurotropic Viruses: Molecular Strategies, Cellular Targets, and Consequences for CNS Infection

Neurotropic viruses have evolved sophisticated mechanisms to evade host immune responses within the central nervous system (CNS), enabling viral replication, persistence, latency, and neuropathogenesis while minimizing irreversible neuronal damage. Unlike peripheral tissues, the CNS requires tightly regulated antiviral immunity to balance effective pathogen control with the preservation of neural function. This review examines the diverse yet convergent immune evasion strategies employed by major neurotropic RNA and DNA viruses, including herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV), rabies virus (RABV), flaviviruses, alphaviruses, enteroviruses, and JC virus (JCV). We discuss viral interference with innate immune sensing pathways, including RIG-I-like receptors (RLRs) and cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS–STING) signaling, inhibition of type I interferon induction and Janus kinase–signal transducer and activator of transcription (JAK–STAT) signaling, modulation of interferon-stimulated effector mechanisms, and disruption of antigen presentation and adaptive immune surveillance. The review further highlights the distinct roles of viral latency, long-term persistence, neuronal–glial interactions, and metabolic reprogramming in facilitating prolonged infection within the CNS. Emerging evidence indicates that successful neurotropic viruses rarely achieve immune evasion through complete suppression of host defenses; instead, they fine-tune antiviral responses to preserve host cell viability while preventing viral clearance. Finally, we discuss current knowledge gaps and emphasize the need for advanced human-relevant models, single-cell and spatial multi-omics, and systems-level approaches to better define virus–host interactions within the CNS. A deeper understanding of these integrated immune evasion networks may reveal novel therapeutic strategies that enhance antiviral immunity while limiting neuroinflammation and preserving neurological function.

Antonios Mouzakis, Vasileios Petrakis, K. Chlichlia · 0 citations
Review Open access Jul 2026

Nef as a driver of immunodeficiency and HIV-associated diseases: insights from mouse models

Nef is a non-structural regulatory protein of human immunodeficiency virus (HIV) that exerts pleiotropic effects on the immune system. In infected cells, Nef modulates the surface expression of molecules critical for immune responses and regulates cytokine production, vesicular trafficking, and lipid metabolism as well as apoptosis and autophagy. Despite significant improvements in antiretroviral therapy (ART), Nef is detected in the circulation of HIV-infected individuals as a soluble protein and in association with virions and extracellular vesicles, and it is regarded as a driver of a broad spectrum of HIV-associated comorbidities. Serum Nef concentrations range from a few to several tens of ng/mL, comparable to systemic levels of certain proinflammatory cytokines in inflammatory diseases. This reflects the fact that the primary sources of Nef are cellular viral reservoirs in which ART does not suppress viral protein expression. Among these reservoirs, long-lived HIV-infected memory CD4+ T cells and tissue-resident macrophages are considered the major contributors to systemic Nef production. Due to the need for a more comprehensive understanding of the in vivo functions of Nef and the molecular mechanisms by which it contributes to HIV-associated pathogenesis, a variety of mouse models expressing Nef were developed. This review summarizes existing transgenic mouse models with cell type-specific Nef expression and humanized mouse models used in HIV research, including models based on Nef-deficient strains. The development and systematic characterization of such models are essential for providing experimental validation for the clinical implementation of Nef inhibitors in combination with established ART.

A. Yakovleva, E. Gorshkova, E. Gubernatorova et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.